- Home
- RARE vs HTGC Comparison
RARE vs HTGC Comparison
Compare RARE & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- HTGC
- Stock Information
- Founded
- RARE 2010
- HTGC 2003
- Country
- RARE United States
- HTGC United States
- Employees
- RARE N/A
- HTGC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- HTGC Investment Managers
- Sector
- RARE Health Care
- HTGC Finance
- Exchange
- RARE Nasdaq
- HTGC Nasdaq
- Market Cap
- RARE 4.2B
- HTGC 3.5B
- IPO Year
- RARE 2014
- HTGC 2005
- Fundamental
- Price
- RARE $42.59
- HTGC $21.46
- Analyst Decision
- RARE Strong Buy
- HTGC Buy
- Analyst Count
- RARE 15
- HTGC 7
- Target Price
- RARE $93.13
- HTGC $21.29
- AVG Volume (30 Days)
- RARE 656.5K
- HTGC 935.2K
- Earning Date
- RARE 02-13-2025
- HTGC 02-13-2025
- Dividend Yield
- RARE N/A
- HTGC 8.76%
- EPS Growth
- RARE N/A
- HTGC N/A
- EPS
- RARE N/A
- HTGC 1.61
- Revenue
- RARE $560,230,000.00
- HTGC $493,591,000.00
- Revenue This Year
- RARE $19.26
- HTGC $8.40
- Revenue Next Year
- RARE $36.92
- HTGC $2.47
- P/E Ratio
- RARE N/A
- HTGC $13.34
- Revenue Growth
- RARE 29.01
- HTGC 7.15
- 52 Week Low
- RARE $37.02
- HTGC $16.95
- 52 Week High
- RARE $60.37
- HTGC $22.04
- Technical
- Relative Strength Index (RSI)
- RARE 44.76
- HTGC 60.13
- Support Level
- RARE $41.73
- HTGC $20.50
- Resistance Level
- RARE $44.98
- HTGC $22.04
- Average True Range (ATR)
- RARE 1.72
- HTGC 0.40
- MACD
- RARE -0.04
- HTGC 0.04
- Stochastic Oscillator
- RARE 18.03
- HTGC 62.34
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.